Clinical Trial Update: Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on cavosonstat (N91115) in cystic fibrosis patients who are heterozygous for F508del-CFTR and a gating mutation and are treated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Cavosonstat (Cavosonstat)
• Ivacaftor (ivacaftor)

Snippet

Sponsor: Nivalis Therapeutics, Inc. | Conditions: Cystic Fibrosis | Phase 2 | Status: UNKNOWN